SOURCE: SciClone Pharmaceuticals, Inc.

SciClone Pharmaceuticals, Inc.

August 28, 2012 06:00 ET

SciClone Pharmaceuticals to Present at Investor Conferences in September 2012

FOSTER CITY, CA--(Marketwire - Aug 28, 2012) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Chief Executive Officer, will present a corporate overview and business update at the BioCentury and Thomson Reuters Newsmakers in the Biotech Industry Conference on September 7, 2012 at 10:00 am ET at the Millennium Broadway Hotel in New York City, and at the Rodman & Renshaw 14th Annual Global Investment Conference on September 10, 2012 at 1:35 pm ET at the Waldorf-Astoria Hotel in New York City.

To access the live audio webcast of these presentations, please log on through a link located in the Investor Relations section of SciClone's website at, under the Calendar of Events tab. A replay of the webcasts will be available one hour after the conclusion of the live events.

Gary Titus, SciClone's Chief Financial Officer, will also participate in the Morgan Stanley Global Healthcare Conference on September 12, 2012 at the Grand Hyatt Hotel in New York City, and at the Morgan Stanley Asia Day at the Four Seasons Hotel in Boston on September 13, 2012.

About SciClone

SciClone Pharmaceuticals is a revenue-generating, profitable, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone's ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers according to the local regulatory approvals. Besides ZADAXIN, SciClone markets about 15 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California. For additional information, please visit

Ambien, Depakine, Stilnox and Tritace are registered trademarks of Sanofi and/or its affiliates.

Aggrastat is a registered trademark of Medicure International Inc. in the United States, and Iroko Cardio LLC in numerous other countries.

SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.

Contact Information